S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

R1 RCM Stock Forecast, Price & News

+1.01 (+4.82%)
(As of 07/1/2022 08:45 PM ET)
Today's Range
50-Day Range
52-Week Range
1.14 million shs
Average Volume
1.26 million shs
Market Capitalization
$6.15 billion
P/E Ratio
Dividend Yield
Price Target

R1 RCM MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
32.0% Upside
$29.00 Price Target
Short Interest
2.40% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
-0.32mentions of R1 RCM in the last 14 days
Based on 22 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.48 to $0.74 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.36 out of 5 stars

Business Services Sector

48th out of 466 stocks

Management Services Industry

2nd out of 8 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

R1 RCM logo

About R1 RCM (NASDAQ:RCM) Stock

R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. It also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. It serves healthcare providers, including health systems, hospitals, and physician groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was incorporated in 2003 and is headquartered in Murray, Utah.

RCM Stock News Headlines

R1 RCM (NASDAQ:RCM) Sees Large Volume Increase
R1 RCM Inc.: R1 RCM Completes Acquisition of Cloudmed
7RCM : R1 RCM: Q1 Earnings Insights
R1 RCM Misses Q1 EPS by 1c
R1 RCM Reports First Quarter 2022 Results
R1 RCM Q1 2022 Earnings Preview
R1 RCM Becomes Oversold
Earnings Outlook For R1 RCM
R1 RCM: Undervalued Stock With 62.5% Upside
See More Headlines

Industry, Sector and Symbol

Management services
Health Care Services
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
$97.20 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.47 billion
Cash Flow
$0.63 per share
Book Value
$1.25 per share


Free Float
Market Cap
$6.15 billion
Not Optionable

Social Links

R1 RCM Frequently Asked Questions

Should I buy or sell R1 RCM stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" R1 RCM stock.
View analyst ratings for R1 RCM
or view top-rated stocks.

What is R1 RCM's stock price forecast for 2022?

8 analysts have issued 1 year target prices for R1 RCM's stock. Their RCM stock forecasts range from $26.00 to $34.00. On average, they predict R1 RCM's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price.
View analysts' price targets for R1 RCM
or view top-rated stocks among Wall Street analysts.

How has R1 RCM's stock performed in 2022?

R1 RCM's stock was trading at $25.49 at the beginning of 2022. Since then, RCM stock has decreased by 13.8% and is now trading at $21.97.
View the best growth stocks for 2022 here

When is R1 RCM's next earnings date?

R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for R1 RCM

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) posted its quarterly earnings data on Monday, May, 9th. The healthcare provider reported $0.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by $0.01. The healthcare provider had revenue of $385.70 million for the quarter, compared to the consensus estimate of $384.18 million. R1 RCM had a net margin of 6.64% and a trailing twelve-month return on equity of 29.44%. The business's revenue for the quarter was up 12.6% compared to the same quarter last year. During the same quarter last year, the company posted ($2.37) EPS.
View R1 RCM's earnings history

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM updated its FY 2022 earnings guidance on Monday, July, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.85 billion-$1.87 billion, compared to the consensus revenue estimate of $1.75 billion.

Who are R1 RCM's key executives?

R1 RCM's management team includes the following people:
  • Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 51, Pay $2.65M)
  • Ms. Rachel Wilson, Exec. VP, CFO & Treasurer (Age 49, Pay $1.47M)
  • Mr. John M. Sparby, Exec. VP of Operations & Delivery and COO (Age 46, Pay $1.01M) (LinkedIn Profile)
  • Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 51, Pay $911.83k)
  • Mr. Richard B. Evans Jr., Sr. VP, Corp. Controller & Chief Accounting Officer (Age 54)
  • Mr. Jay Sreedharan, Chief Technology & Digital Officer
  • Mr. Atif A. Rahim, Sr. VP of Investor Relations & Bus. Devel.
  • Mr. Corey Perman, Exec. VP of Compliance & Risk
  • Mr. Sean Radcliffe, Exec. VP, Gen. Counsel & Corp. Sec.
  • Ms. Kate Sanderson, Exec. VP & Chief HR Officer

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM CEO Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among R1 RCM's employees.

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by many different retail and institutional investors. Top institutional investors include Insight Wealth Strategies LLC (0.03%). Company insiders that own R1 RCM stock include Achi Series Lllp Tcp-Asc, Albert Rene Zimmerli, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, Michael C Feiner and Richard B Jr Evans.
View institutional ownership trends for R1 RCM

Which major investors are selling R1 RCM stock?

RCM stock was sold by a variety of institutional investors in the last quarter, including Insight Wealth Strategies LLC. Company insiders that have sold R1 RCM company stock in the last two years include Achi Series Lllp Tcp-Asc, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, Michael C Feiner, and Richard B Jr Evans.
View insider buying and selling activity for R1 RCM
or view top insider-selling stocks.

How do I buy shares of R1 RCM?

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $21.97.

How much money does R1 RCM make?

R1 RCM (NASDAQ:RCM) has a market capitalization of $6.15 billion and generates $1.47 billion in revenue each year. The healthcare provider earns $97.20 million in net income (profit) each year or $0.31 on an earnings per share basis.

How many employees does R1 RCM have?

R1 RCM employs 22,000 workers across the globe.

Does R1 RCM have any subsidiaries?

The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Cerner RevWorks, Clearsight Intermediate Holdings Inc., Cloudmed, Flare Capital Partners Investment Company, Intermedix, Intermedix ARM LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Staffing Inc., Medical Consultants Inc., Practice Support Resources LLC, Project Links Parent Inc., Project Roadrunner Merger Sub Inc., Project Roadrunner Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCHEDULING.COM INC., SCI Solutions, Tonic Health LLC, VisitPay, cGate Health Inc., and iVinci Partners LLC.
Read More

When was R1 RCM founded?

R1 RCM was founded in 2003.

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The official website for R1 RCM is www.r1rcm.com. The healthcare provider can be reached via phone at (312) 324-7820, via email at arahim@r1rcm.com, or via fax at 302-655-5049.

This page (NASDAQ:RCM) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.